Recently, Egler et al (2008) have shown that serum IL-6 levels were elevated in patients with high-risk neuroblastoma, whereas sIL-6R levels followed an inverse relationship with disease such that lower levels were present in the patients with metastatic disease. This evidence concerns the gene IL6 and metastatic neoplasm.